Last reviewed · How we verify

Cantil — Competitive Intelligence Brief

Cantil (MEPENZOLATE) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Anticholinergic. Area: Gastroenterology.

marketed Anticholinergic Muscarinic acetylcholine receptor M2 Gastroenterology Small molecule Live · refreshed every 30 min

Target snapshot

Cantil (MEPENZOLATE) — Sanofi.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Cantil TARGET MEPENZOLATE Sanofi marketed Anticholinergic Muscarinic acetylcholine receptor M2 1956-01-01
Toviaz Fesoterodine Fumarate Pfizer marketed fesoterodine Muscarinic acetylcholine receptor M2 2008-01-01
Toviaz FESOTERODINE Pfizer marketed fesoterodine Muscarinic acetylcholine receptor M2 2008-01-01
HEXOCYCLIUM HEXOCYCLIUM AbbVie marketed hexocyclium Muscarinic acetylcholine receptor M1, Muscarinic acetylcholine receptor M2, Muscarinic acetylcholine receptor M3 1982-01-01
Syncurine DECAMETHONIUM marketed decamethonium Acetylcholinesterase, Histamine H3 receptor, Muscarinic acetylcholine receptor M2 1975-01-01
Kemadrine PROCYCLIDINE marketed Muscarinic acetylcholine receptor M1, Muscarinic acetylcholine receptor M2, Muscarinic acetylcholine receptor M3 1955-01-01
Quinidine Gluconate QUINIDINE SULFATE Eli Lilly marketed Antiarrhythmic Muscarinic acetylcholine receptor M2 1950-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Anticholinergic class)

  1. · 4 drugs in this class
  2. Pearl Therapeutics, Inc. · 3 drugs in this class
  3. Shionogi · 2 drugs in this class
  4. Ain Shams University · 1 drug in this class
  5. Astellas Pharma Inc · 1 drug in this class
  6. Boehringer Ingelheim · 1 drug in this class
  7. Covis · 1 drug in this class
  8. Forest Labs Inc · 1 drug in this class
  9. Fougera Pharms · 1 drug in this class
  10. Glaxo Grp England · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Cantil — Competitive Intelligence Brief. https://druglandscape.com/ci/mepenzolate. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators: